Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01587352 · ClinicalTrials.gov registry record · Phase 2
Vorinostat in Treating Patients With Metastatic Melanoma of the Eye
A Phase 2 study of Metastatic Uveal Melanoma and Stage IV Uveal Melanoma AJCC v7, sponsored by National Cancer Institute (NCI).
- Active
- Registry status
- Phase 2
- Development phase
- 40
- Enrollment target
- 3
- Study locations
NCT01587352: Active Phase 2 study of Metastatic Uveal Melanoma and Stage IV Uveal Melanoma AJCC v7, sponsored by National Cancer Institute (NCI).
NCT01587352 is a Phase 2 study of Metastatic Uveal Melanoma and Stage IV Uveal Melanoma AJCC v7 that is active but no longer recruiting, run by National Cancer Institute (NCI). The registered enrollment target is 40 participants, below the 130-participant average among 14 other Metastatic Uveal Melanoma trials with a reported enrollment target (69% lower). The trial reports 3 study locations across 2 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT01587352, a Phase 2 study of Metastatic Uveal Melanoma and Stage IV Uveal Melanoma AJCC v7, is active but no longer recruiting, sponsored by National Cancer Institute (NCI).
- ACTIVE NOT RECRUITING
- Registry status
- Phase 2
- Development phase
- 40 participants
- Enrollment target
- 3
- Study locations
Study Summary
This phase II trial studies how well vorinostat works in treating patients with melanoma of the eye that has spread to other parts of the body (metastatic). Vorinostat may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth.
Primary Outcome
Defined as the rate of complete and partial responses. The response rate along with 90% confidence interval will be estimated.
Conditions Studied
Interventions
- OTHER Laboratory Biomarker Analysis
- DRUG Vorinostat
Study Locations (3)
New York
- NYP/Columbia University Medical Center/Herbert Irving Comprehensive Cancer Center - New York
- Memorial Sloan Kettering Cancer Center - New York
Tennessee
- Vanderbilt University/Ingram Cancer Center - Nashville
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 40 participants |
| Start Date | 2012-05-29 |
| Est. Completion | 2026-12-31 |
| Phase | Phase 2 |
What the registry record for NCT01587352 still lists
NCT01587352 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 40 participants, a relatively small participant target, below the 130-participant average among 14 other Metastatic Uveal Melanoma trials with a reported enrollment target (69% lower).
The record links to 2 conditions, with Metastatic Uveal Melanoma appearing as the primary indexed condition, and to 2 interventions - of which Laboratory Biomarker Analysis is the first listed.
NCT01587352 reports a single indexed study location in New York, Tennessee.
Frequently Asked Questions
What is clinical trial NCT01587352 about?
NCT01587352 is a clinical study titled "Vorinostat in Treating Patients With Metastatic Melanoma of the Eye". This phase II trial studies how well vorinostat works in treating patients with melanoma of the eye that has spread to other parts of the body (metastatic). Vorinostat may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth.
What is the current status of trial NCT01587352?
This trial is currently active not recruiting. It is a Phase 2 study. The enrollment target is 40 participants. The study started on 2012-05-29. Estimated completion is 2026-12-31.
What conditions does trial NCT01587352 study?
This clinical trial studies the following conditions: Metastatic Uveal Melanoma, Stage IV Uveal Melanoma AJCC v7.
What interventions are being tested in trial NCT01587352?
The interventions under investigation include: Laboratory Biomarker Analysis (OTHER), Vorinostat (DRUG).
Who is sponsoring clinical trial NCT01587352?
This trial is sponsored by National Cancer Institute (NCI), which has 3,257 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT01587352 being conducted?
This trial has 3 study locations across New York, Tennessee. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Metastatic Uveal Melanoma
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT01587352's enrollment target sits among peer trials
40 8th of 14 higher than 7 of 14 other Metastatic Uveal Melanoma trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Metastatic Uveal Melanoma trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Study of Tebentafusp and Radioembolization in the Treatment of Metastatic Uveal Melanoma
RECRUITING · Phase 2
-
A Randomized, Phase 2/3 Study to Investigate the Efficacy and Safety of RP2 in Combination With Nivolumab in Immune Checkpoint Inhibitor-Naïve Adult Patients With Metastatic Uveal Melanoma
RECRUITING · Phase 2
-
Study of Cemiplimab Plus Ziv-Aflibercept for Subjects With Metastatic Uveal Melanoma
RECRUITING · Phase 2
-
Phase 2 Combination of Melphalan/HDS Via PHP + Tebentafusp in Treating Metastatic Uveal Melanoma
RECRUITING · Phase 2
-
Transarterial Chemoembolization for the Treatment of Uveal Melanoma With Liver Metastases
ACTIVE NOT RECRUITING · Phase 2
-
Binimetinib Plus Belinostat for Subjects With Metastatic Uveal Melanoma
ACTIVE NOT RECRUITING · Phase 2
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT01306019 · 40 participants · Phase 1
Lentiviral Gene Transfer for Treatment of Children Older Than Two Years of Age With X-Linked Severe Combined Immunodeficiency (XSCID)
- NCT01608152 · 40 participants
Development of a Video Game for the Improvement of Outcomes in Stem Cell Transplant Survivors
- NCT01668082 · 40 participants · NA
An Investigation of Brain Tumor Metabolism in Patients Undergoing Surgical Resection
- NCT02015013 · 40 participants · Phase 2
Hematopoietic Stem Cell Mobilization in Idiopathic CD4 Lymphocytopenia Patients and Healthy Controls for the Study of T Cell Maturation and Trafficking in Murine Models
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI